• OPEN AN ACCOUNT
Indian Indices
Nifty
25,069.20 -44.80
(-0.18%)
Sensex
81,785.74 -118.96
( -0.15%)
Bank Nifty
54,887.85 78.55
( 0.14%)
Nifty IT
35,902.20 -208.55
( -0.58%)
Global Indices
Nasdaq
45,857.35 271.66
(-0.59%)
Dow Jones
6,605.38 -3.09
(-0.05%)
Hang Seng
44,778.02 405.52
(0.91%)
Nikkei 225
9,277.03 -6.26
(-0.07%)
Forex
USD-INR
88.28 0.18
(0.20%)
EUR-INR
103.39 0.27
(0.26%)
GBP-INR
119.55 0.32
(0.27%)
JPY-INR
0.60 0.00
(0.17%)

EQUITY - MARKET SCREENER

Natural Capsules Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524654
INE936B01015
160.8315223
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATCAPSUQ
25.92
201.6
EPS(TTM)
Face Value()
Div & Yield %
7.52
10
0
 

Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.